Charles Cowey, MD
Medical Oncology · Dallas, TXNPI 1033358288
Payments from drug & device makers
Across 1,578 payments — averaging $4207.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.5M
- E.r. Squibb & Sons, L.L.C.$1.2M
- Amgen$980K
- Seagen Inc.$628K
- Modernatx, Inc.$359K
- Regeneron$167K
- plus $773K from 29 others
Across 35 payments — averaging $427.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$8K
- Novartis$7K
What the payments were for
- Consulting fees$26,85977%
- Speaking & faculty fees$2,5207%
- Food & beverage$7252%
- Education$4,56913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 158 | $2,500,754 |
| E.r. Squibb & Sons, L.L.C. | 73 | $1,231,137 |
| Amgen | 29 | $980,429 |
| Seagen Inc. | 659 | $628,030 |
| Modernatx, Inc. | 89 | $358,910 |
| Regeneron | 72 | $167,209 |
| Hoffmann-la Roche Limited | 24 | $91,457 |
| AstraZeneca | 10 | $83,223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $81,839 |
| Pfizer | 68 | $78,129 |
| Springworks Therapeutics, Inc. | 170 | $77,513 |
| Daiichi Sankyo Inc. | 16 | $58,522 |
| Karyopharm Therapeutics Inc. | 15 | $58,259 |
| Immunocore Limited | 6 | $48,304 |
| Exelixis Inc. | 11 | $44,520 |
| AVEO Pharmaceuticals, Inc. | 8 | $37,000 |
| Array Biopharma Inc | 40 | $34,477 |
| Genentech, Inc. | 45 | $26,714 |
| Novartis | 8 | $20,952 |
| EMD Serono, Inc. | 4 | $16,468 |
| GSK | 9 | $7,027 |
| Eisai Inc. | 3 | $2,847 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,620 |
| Iovance Biotherapeutics, Inc. | 1 | $2,000 |
| Astrazeneca UK Limited | 1 | $194 |
| AbbVie | 9 | $146 |
| Siemens Medical Solutions USA, Inc. | 5 | $73 |
| Astellas Pharma US Inc | 3 | $67 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $57 |
| Johnson & Johnson | 1 | $26 |
| Genentech USA, Inc. | 2 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Tempus AI, Inc | 1 | $22 |
| Sanofi | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,638,990 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 18 | $460,104 |
| InlytaAxitinib | 23 | $418,917 |
| LenvimaLenvatinib Mesylate | 16 | $374,266 |
| MektoviBinimetinib | 23 | $339,062 |
| XtandiEnzalutamide | 24 | $334,093 |
| BraftoviEncorafenib | 19 | $298,150 |
| ErleadaApalutamide | 20 | $281,794 |
| MekinistTrametinib Dimethyl Sulfoxide | 15 | $221,527 |
| TafinlarDabrafenib Mesylate | 13 | $174,754 |
| Pazopanib Hcl | 12 | $118,935 |
| Imatinib Mesylate | 20 | $40,225 |
| Abiraterone Acetate | 52 | $31,681 |
| EliquisApixaban | 24 | $14,065 |
| Hydrocortisone | 27 | $1,735 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Array Biopharma IncMektovi, Braftovi | $34,477 | $637,21242 claims |
| Exelixis Inc.Cabometyx | $44,520 | $460,10418 claims |
| PfizerInlyta, Eliquis | $78,129 | $432,98247 claims |
| NovartisMekinist, Tafinlar | $20,952 | $396,28228 claims |
| Eisai Inc.Lenvima | $2,847 | $374,26616 claims |
| Astellas Pharma US IncXtandi | $67 | $334,09324 claims |
| Johnson & JohnsonErleada | $26 | $281,79420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Sawsan RashdanDallas$29.9M
- David GerberDallas$22.8M
- Joyce O'ShaughnessyDallas$20.8M
- Moshe LevyDallas$19.7M
- Minal BarveDallas$16.7M
- Andrew PaulsonDallas$11.5M
- Hans HammersDallas$11.4M
- James StraussDallas$9.1M
- Larry AndersonDallas$8.7M
- Heather McArthurDallas$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.